TopoGEN

Executive Summary

TopoGEN is a specialized biotechnology company founded in 1990, headquartered in Port Orange, Florida. It is a leading provider of research tools focused on DNA topology and repair, including purified topoisomerase enzymes, assay kits, antibodies, and cell-based reporter systems. The company's core mission is to support academic, pharmaceutical, and biotechnology researchers in cancer drug discovery and basic research involving topoisomerase-targeting agents. With over 35 years of experience, TopoGEN has established a loyal customer base but operates in a niche market with limited growth potential. As a private company with no disclosed funding or valuation, its financial transparency is low. The company's products are essential for researchers studying DNA topology, but the addressable market is relatively small, and competition from larger biotech tool providers exists. Overall, TopoGEN represents a stable but low-growth opportunity in the diagnostics and antibodies space.

Upcoming Catalysts (preview)

• Q3 2026Launch of new topoisomerase II alpha assay kit60% success
• Q4 2026Strategic collaboration with a major pharmaceutical company for drug screening services50% success
• 2027Expansion into CRISPR-based DNA repair tools40% success